ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
| (e) | On June6, 2018, the stockholders of ACADIA Pharmaceuticals Inc. (“Registrant”) approved an amendment to Registrant’s 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares. |
The foregoing description of Registrant’s 2010 Equity Incentive Plan, as amended, does not purport to be complete, and is qualified in its entirety by reference to Exhibit 99.1 to this Report, as well as the description of the 2010 Equity Incentive Plan, as amended, included in Registrant’s definitive proxy statement (the “proxy statement”) filed with the Securities and Exchange Commission on April30, 2018.
Item 5.02 Submission of Matters to a Vote of Security Holders.
| (a) | Registrant held its 2018 Annual Meeting of Stockholders on June6, 2018 (the “2018 Annual Meeting”). |
| (b) | The election of three nominees to serve as ClassII directors on Registrant’s Board of Directors (the “Board”) until Registrant’s 2021 Annual Meeting of Stockholders was carried out at the 2018 Annual Meeting. The following three ClassII directors were elected by the votes indicated: |
| For | Withheld | BrokerNon-Votes | |
|
Julian Baker |
76,696,395 | 13,522,151 | 20,781,527 |
|
Stephen Biggar |
74,252,647 | 15,965,899 | 20,781,527 |
|
Daniel Soland |
85,556.422 | 4,662,124 | 20,781,527 |
In addition to the election of three ClassII directors, the following matters were submitted to a vote of the stockholders at the 2018 Annual Meeting:
| (i) | the approval of an amendment to Registrant’s 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares, which was approved by the following vote: |
| For | Against | Abstain | BrokerNon-Votes |
| 54,418,954 | 35,616,191 | 183,401 | 20,781,527 |
| (ii) | the approval, on an advisory basis, of the compensation of Registrant’s named executive officers, as disclosed in the proxy statement, which was approved by the following vote: |
| For | Against | Abstain | BrokerNon-Votes |
| 53,635,912 | 36,369,150 | 213,484 | 20,781,527 |
| (iii) | the appointment of Ernst& Young LLP as Registrant’s independent registered public accounting firm for the fiscal year ending December31, 2018 was ratified by the following vote: |
| For | Against | Abstain |
| 110,130,114 | 368,768 | 501,191 |
Each of the foregoing voting results from the 2018 Annual Meeting is final.
Item 5.02 Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
Description |
| 99.1 | 2010 Equity Incentive Plan, as amended |
ACADIA PHARMACEUTICALS INC ExhibitEX-99.1 2 d589769dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ACADIA PHARMACEUTICALS INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 12,…To view the full exhibit click here
About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist (SSIA), targeting 5-HT2A receptors. The Company’s Pimavanserin is a chemical entity, which has completed Phase III development, and is indicated for the treatment of Parkinson’s disease psychosis. NUPLAZID (pimavanserin) is a selective serotonin inverse agonist preferentially targeting the 5-HT2A receptor, a key serotonin receptor that plays a role in psychosis. Through this mechanism, NUPLAZID has demonstrated efficacy in Parkinson’s disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics.
